Study of Onivyde and 5-FU in Combination With Xilonix for Pancreatic Cancer With Cachexia
Status:
Completed
Trial end date:
2020-10-27
Target enrollment:
Participant gender:
Summary
This study is being conducted to examine the safety of the investigational drug, Xilonix(™),
in addition to standard doses of Onivyde® (nanoliposomal irinotecan) and 5- fluorouracil
(5FU)/folinic acid (leucovorin) for pancreatic cancer patients with cachexia. Cachexia is a
syndrome that includes involuntary weight loss and physical deterioration that can contribute
to poor outcomes of cancer treatment. In other studies, Xilonix has increased lean body mass
in advanced cancer patients. This increase could lead to improved weight maintenance and
quality of life.
Phase:
Phase 1
Details
Lead Sponsor:
Andrew Hendifar, MD
Collaborators:
Ipsen Janssen Research & Development, LLC XBiotech, Inc.